Free Trial
NASDAQ:BNBX

Applied Dna Sciences Q4 2025 Earnings Results & Report

Applied Dna Sciences logo
$0.09 0.00 (0.00%)
As of 11/13/2026 11:30 AM Eastern

Applied Dna Sciences reported Q4 2025 earnings on December 19, 2025. The company reported EPS of $122.52, while revenue was $199.43 thousand.

Earnings Announcement Details

Quarter
Q4 2025
Time
After Market Closes

Applied Dna Sciences EPS Results

Actual EPS
$122.52
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Applied Dna Sciences Revenue Results

Actual Revenue
$199.43 thousand
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Applied Dna Sciences Q4 2025 Earnings FAQ

Applied Dna Sciences (NASDAQ:BNBX) reported earnings of $122.52 per share for Q4 2025. The report was announced on Friday, December 19, 2025.

Applied Dna Sciences reported revenue of $199.43 thousand for Q4 2025.

Applied Dna Sciences Earnings Headlines

URGENT: If you own a home, please review the map below.
More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards urges homeowners to check the map and see whether one is near them. Families in Georgia have been forced to sell, entire Ohio neighborhoods are being torn down, and nearly 50,000 Lake Tahoe residents face losing power. Rickards advised the Pentagon and the U.S. intelligence community for decades. He says one man outside Washington can stop it.tc pixel
See More Applied Dna Sciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Applied Dna Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Applied Dna Sciences and other key companies, straight to your email.

About Applied Dna Sciences

Applied Dna Sciences (NASDAQ:BNBX), Inc. is a biotechnology company that develops DNA-based technologies for molecular diagnostics, therapeutics and industrial applications. Its platform is designed to produce and analyze DNA for use in areas including infectious disease testing, genetic medicine and product authentication.

The company has also developed DNA-based supply-chain and anti-counterfeiting solutions, including technologies intended to help authenticate textiles, pharmaceutical products and other goods. Applied DNA Sciences has served commercial, healthcare and government-related customers, primarily in the United States, while pursuing additional international applications for its technologies.

Applied DNA Sciences is generally identified by the Nasdaq ticker APDN; the ticker BNBX does not appear to correspond to the company. The company was founded in 2003 and has historically been led by Chief Executive Officer James A. Hayward.

View Applied Dna Sciences Profile